Genethera Stock Performance
| GTHR Stock | USD 0.0001 0.00 0.00% |
The company retains a Market Volatility (i.e., Beta) of 0.0, which attests to not very significant fluctuations relative to the market. the returns on MARKET and GeneThera are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days GeneThera has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable technical indicators, GeneThera is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors. ...more
GeneThera |
GeneThera Relative Risk vs. Return Landscape
If you would invest 0.01 in GeneThera on August 26, 2024 and sell it today you would earn a total of 0.00 from holding GeneThera or generate 0.0% return on investment over 90 days. GeneThera is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than GeneThera, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
GeneThera Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for GeneThera's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as GeneThera, and traders can use it to determine the average amount a GeneThera's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| GTHR |
Based on monthly moving average GeneThera is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of GeneThera by adding GeneThera to a well-diversified portfolio.
GeneThera Fundamentals Growth
GeneThera Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of GeneThera, and GeneThera fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on GeneThera Pink Sheet performance.
| Return On Asset | -95.38 | |||
| Current Valuation | 1.44 M | |||
| Shares Outstanding | 35.33 M | |||
| Price To Earning | (0.17) X | |||
| EBITDA | (1 M) | |||
| Cash And Equivalents | 140.1 K | |||
| Total Debt | 806.87 K | |||
| Book Value Per Share | (0.24) X | |||
| Cash Flow From Operations | (8.57 K) | |||
| Earnings Per Share | (0.03) X | |||
| Total Asset | 6.3 K | |||
| Retained Earnings | (25.59 M) | |||
| Current Asset | 55 K | |||
| Current Liabilities | 7.08 M | |||
About GeneThera Performance
Assessing GeneThera's fundamental ratios provides investors with valuable insights into GeneThera's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the GeneThera is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
GeneThera, Inc., a biotechnology company, develops molecular assays and therapeutics for the detection and treatment of zoonotic diseases. The companys Molecular RoboticAI Platform and Therapeutic strategy is designed to prevent the spread of disease from animals and allow to better control of zoonotic infectious agents. Genethera operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 2 people.Things to note about GeneThera performance evaluation
Checking the ongoing alerts about GeneThera for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for GeneThera help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| GeneThera generated a negative expected return over the last 90 days | |
| GeneThera has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (1.01 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| GeneThera currently holds about 140.1 K in cash with (8.57 K) of positive cash flow from operations. | |
| Roughly 18.0% of the company shares are held by company insiders |
- Analyzing GeneThera's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether GeneThera's stock is overvalued or undervalued compared to its peers.
- Examining GeneThera's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating GeneThera's management team can have a significant impact on its success or failure. Reviewing the track record and experience of GeneThera's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of GeneThera's pink sheet. These opinions can provide insight into GeneThera's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for GeneThera Pink Sheet Analysis
When running GeneThera's price analysis, check to measure GeneThera's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneThera is operating at the current time. Most of GeneThera's value examination focuses on studying past and present price action to predict the probability of GeneThera's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneThera's price. Additionally, you may evaluate how the addition of GeneThera to your portfolios can decrease your overall portfolio volatility.